KLP Kapitalforvaltning AS Sells 34,400 Shares of Moderna, Inc. $MRNA

KLP Kapitalforvaltning AS lowered its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 32.2% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 72,400 shares of the company's stock after selling 34,400 shares during the quarter. KLP Kapitalforvaltning AS's holdings in Moderna were worth $1,998,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of MRNA. S Bank Fund Management Ltd bought a new position in shares of Moderna during the 1st quarter worth approximately $25,000. TD Private Client Wealth LLC raised its holdings in shares of Moderna by 348.8% in the 2nd quarter. TD Private Client Wealth LLC now owns 956 shares of the company's stock worth $26,000 after purchasing an additional 743 shares during the period. SVB Wealth LLC bought a new stake in shares of Moderna in the 1st quarter worth approximately $28,000. CX Institutional raised its holdings in shares of Moderna by 1,129.8% in the 2nd quarter. CX Institutional now owns 1,033 shares of the company's stock worth $29,000 after purchasing an additional 949 shares during the period. Finally, Costello Asset Management INC bought a new stake in shares of Moderna in the 1st quarter worth approximately $30,000. Institutional investors own 75.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Bank of America lowered their price target on shares of Moderna from $26.00 to $25.00 and set an "underperform" rating on the stock in a report on Tuesday, July 22nd. Cowen assumed coverage on shares of Moderna in a report on Sunday, July 13th. They issued a "hold" rating on the stock. Leerink Partners lowered their price target on shares of Moderna from $18.00 to $15.00 and set an "underperform" rating on the stock in a report on Friday, August 22nd. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Moderna in a report on Wednesday, October 8th. Finally, Morgan Stanley lifted their price target on shares of Moderna from $31.00 to $32.00 and gave the stock an "equal weight" rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, fourteen have assigned a Hold rating and five have given a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $41.81.

Moderna Price Performance

Shares of MRNA stock opened at $26.83 on Monday. The company's fifty day simple moving average is $25.92 and its two-hundred day simple moving average is $27.14. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $59.73. The stock has a market capitalization of $10.48 billion, a price-to-earnings ratio of -3.56 and a beta of 2.01.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.99) by $0.86. The business had revenue of $142.00 million for the quarter, compared to analysts' expectations of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The business's revenue for the quarter was down 41.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.